Conferences
ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
ESMO 2020
18 - 22 Sep 2020
Online, Global
SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-sma...
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
Sotorasib for advanced non-small cell lung cancer
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
OS results from SOLAR-1: Alpelisib plus fulvestrant for HR positive, HER2 negati...
Prof Fabrice André - Institut Gustave Roussy, Paris, France
29 Sep 2020
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
28 Sep 2020
Nivolumab for oesophageal cancer following chemoradiation therapy
Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA
25 Sep 2020
PROFound trial and other recent updates in prostate cancer
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
25 Sep 2020
ESMO 2020 renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
25 Sep 2020
Exon 20 insertions in NSCLC - ESMO 2020
Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro
25 Sep 2020
ESMO 2020: Lung cancer latest
Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Po...
25 Sep 2020
Highlights from ESMO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
25 Sep 2020
Latest in bladder cancer with FGFR 2 and 3 mutations
Dr Yohann Loriot and Dr Scott Tagawa
24 Sep 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer
Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan
24 Sep 2020
Disparities in access to oncology clinical trials across Europe
Prof Ana Carneiro - Lund University, Lund, Sweden
24 Sep 2020
ESMO 2020: Latest updates in prostate cancer
Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Johann De Bono and Prof Nick Jam...
23 Sep 2020
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients wit...
Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA
23 Sep 2020
ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer p...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
23 Sep 2020
Breast cancer roundup from ESMO 2020
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
23 Sep 2020
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer
Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA
22 Sep 2020
ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer
Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan
22 Sep 2020
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
22 Sep 2020
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC aft...
Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan
22 Sep 2020
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers
Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany
22 Sep 2020
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
22 Sep 2020
Estimate of the 2-year oncology workload generated by each new patient: A real-w...
Dr Silvio Ken Garattini - University of Udine, Udine, Italy
21 Sep 2020
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NS...
Dr Alex Spira and Dr Joshua Sabari
21 Sep 2020
Impact of COVID-19 pandemic on cancer care: A global collaborative study
Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Ara...
21 Sep 2020
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer
Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK
21 Sep 2020
LungART: Radiotherapy after surgery for patients with non small cell lung cancer
Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France
21 Sep 2020
Personalised molecularly matched therapies for carcinomas of unknown primary
Dr Jacob Adashek - University of South Florida, Tampa, USA
21 Sep 2020
Impact of COVID-19 on oncology professionals
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
20 Sep 2020
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advan...
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
20 Sep 2020
Comparing real world evidence to phase III data on apalutamide for nmCRPC
Prof Heather Payne and Prof Stéphane Oudard
19 Sep 2020
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC
Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France
19 Sep 2020
